Nitish Jha

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

Mary O’Brien, Luis Paz‐Ares, Sandrine Marréaud et al. · The Lancet Oncology · 2022 · 696 citations

Interim Analysis, Surgical Oncology, Oncology +8

VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study

L. Paz-Ares, E O’Brien, M. Mauer et al. · Annals of Oncology · 2022 · 71 citations

Medicine, Clinical Trials, Adjuvant Chemotherapy +9

EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use.

Mary O’Brien, Luis Paz‐Ares, Nitish Jha et al. · Journal of Clinical Oncology · 2022 · 20 citations

Surgical Oncology, Disease Burden, Adjuvant Chemotherapy +17

120MO Adjuvant pembrolizumab versus placebo for early-stage NSCLC after resection and optional chemotherapy: Updated results from PEARLS/KEYNOTE-091

Benjamin Besse, Libor Havel, Solange Peters et al. · Immuno-Oncology Technology · 2023 · 11 citations · Full text